title: Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.
abstract: Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neurons, potentially causing symptom relief and nerve regeneration, and in addition has numerous other effects on metabolic function that might be of benefit in such patients.ALC has been given to HIV patients with symptomatic ATN in a number of clinical studies administered either twice daily intramuscularly or as oral sachets or tablets. It has been shown to significantly reduce a variety of validated pain ratings, and is generally safe and well tolerated. Using a measure of neuronal innervation in standardised skin biopsies of the affected area, cutaneous nerve density has been improved by the administration of ALC in subjects with symptomatic ATN and reduced epidermal and dermal innervation, associated with clinical improvement, which was maintained over a 4-year period. Improvements were seen in both the structure and function of small sensory fibres, which were sustained over time whilst subjects received ALC. Other open-label, non-randomised studies have shown similar benefits in patients with ATN in terms of pain reduction over the short term. Further placebo-controlled studies of both treatment and prophylaxis have been completed and are under analysis to characterise further the usefulness of this pathogenesis-based therapy for ATN.
authors: Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK. mike@mikeyoule.com
authors: Mike
authors: M
authors: Youle
mesh_terms: D000108:Acetylcarnitine / Q000627:therapeutic use*; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018697:Nootropic Agents; D000108:Acetylcarnitine
references: Neurology. 1998 Dec;51(6):1682-8
references: 9855523
references: Int J Clin Pharmacol Res. 1992;12(5-6):225-30
references: 1284498
references: Neurochem Res. 1991 Jan;16(1):63-6
references: 2052139
references: Neurology. 1995 Oct;45(10):1848-55
references: 7477980
references: Brain Res Dev Brain Res. 1991 Apr 24;59(2):221-30
references: 1655307
references: J Neurosci Res. 1988 Aug;20(4):491-6
references: 2846861
references: HIV Med. 2006 Nov;7(8):487-503
references: 17105508
references: Exp Brain Res. 2002 Jul;145(2):182-9
references: 12110958
references: AIDS. 2002 Feb 15;16(3):407-12
references: 11834952
references: Drug Saf. 1998 Dec;19(6):481-94
references: 9880091
references: Mol Pharmacol. 2002 May;61(5):989-96
references: 11961116
references: Neuropharmacology. 2002 Dec;43(7):1180-7
references: 12504925
references: AIDS. 2004 Jul 23;18(11):1549-60
references: 15238773
references: Pharmacol Res. 1995 Dec;32(6):383-9
references: 8736490
references: HIV Clin Trials. 2005 Nov-Dec;6(6):344-50
references: 16566084
references: Mol Pharmacol. 1991 May;39(5):625-8
references: 1851960
references: Neuropathol Appl Neurobiol. 1998 Oct;24(5):373-80
references: 9821168
references: Int J Dev Neurosci. 1992 Aug;10(4):321-9
references: 1414444
references: Int J Tissue React. 1999;21(1):1-6
references: 10463134
references: Eur J Clin Pharmacol. 1989;37(1):59-63
references: 2591464
references: Drugs R D. 2002;3(4):223-31
references: 12455197
references: Neurology. 2000 Mar 14;54(5):1080-8
references: 10720278
references: J Clin Chem Clin Biochem. 1990 May;28(5):297-301
references: 2199593
references: Eur J Clin Pharmacol. 1992;42(1):89-93
references: 1541322
references: Int J Clin Pharmacol Res. 1995;15(1):9-15
references: 7490173
references: J Clin Invest. 1996 Apr 15;97(8):1900-7
references: 8621774
references: Am J Med. 1998 Feb;104(2):129-36
references: 9528730
references: Neurochem Res. 1992 Jul;17(7):671-5
references: 1407262
references: Biochem Pharmacol. 1991 Jun 21;42(1):R5-8
references: 1648918
references: Neurosci Lett. 2002 Dec 16;334(3):181-5
references: 12453625
references: Clin Drug Investig. 1995 Dec;10(6):317-22
references: 27519331
references: J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):153-61
references: 7749792
references: Neurol Res. 1989 Mar;11(1):57-62
references: 2565553
references: AIDS. 1997 Feb;11(2):185-90
references: 9030365
references: HIV Med. 2007 May;8(4):241-50
references: 17461852
references: J Endocrinol Invest. 2004;27(6 Suppl):171-6
references: 15481819
references: Neurology. 2002 Jan 8;58(1):115-9
references: 11781415
references: Clin Drug Investig. 1998;15(2):73-9
references: 18370471
references: J Neurol. 2004 Oct;251(10):1260-6
references: 15503108
references: Acta Neurol (Napoli). 1992 Feb;14(1):15-21
references: 1580200
references: Neuropharmacology. 2004 Aug;47(2):286-94
references: 15223307
references: J Peripher Nerv Syst. 1997;2(3):250-2
references: 10975731
references: AIDS. 2000 Feb 18;14(3):273-8
references: 10716503
references: AIDS. 1998 Oct 1;12(14):1735-44
references: 9792373
references: Nat Med. 1995 May;1(5):417-22
references: 7585087
references: Arch Neurol. 1991 Dec;48(12):1273-4
references: 1668978
references: J Peripher Nerv Syst. 2006 Mar;11(1):72-6
references: 16519785